In our results, the APOE ε4 status was associated with lower CSF Aβ42, as well as higher CSF T-tau and p-tau protein levels and tau/Aβ42 ratios, in the early prodromal stages of AD patients and in the control subjects, taking into account the influence of age. Here, MAPT is linked to Alzheimer disease.